Literatur
Ford M, Koehn B, Wagener M et al (2007) Antigen-specific precursor frequency impacts T cell proliferation, differentiation, and requirement for costimulation. J Exp Med 204:299–309
Gao W, Lu Y, El Essawy B et al (2007) Contrasting effects of cyclosporine and rapamycin in de novo generation of alloantigen-specific regulatory T cells. Am J Transplant 7:1722–1732
Rostaing L, Vincenti F, Grinyó J et al (2013) Long-term belatacept exposure maintains efficacy and safety at 5 years: results from the long-term extension of the BENEFIT study. Am J Transplant 13:2875–2883
Vincenti F, Larsen C, Durrbach A et al (2005) Costimulation blockade with belatacept in renal transplantation. N Engl J Med 353:770–781
Xu H, Perez S, Cheeseman J et al (2014) The allo- and viral-specific immunosuppressive effect of belatacept, but not tacrolimus, attenuates with progressive T cell maturation. Am J Transplant 14:319–332
Interessenkonflikt
J. Beimler weist auf folgende Beziehungen hin: Vortragshonorar von Bristol-Myers Squibb.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Beimler, J. Einsatz von Belatacept nach Nierentransplantation ohne Erhaltungstherapie mit Steroiden oder Calcineurininhibitoren. Nephrologe 10, 49–50 (2015). https://doi.org/10.1007/s11560-014-0915-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11560-014-0915-8